, localized on chromosome 12, is considered a negative regulator of p53 function and seems to play a role in the pathogenesis of a variety of tumors. The mdm2 amplification in advanced-stage gastric carcinoma has not yet been investigated.
The mdm2 gene has been mapped to chromosome 12q13-14 and encodes a 90 kDa cellular oncoprotein. The gene structure on the human chromosome was identified in 1992 (1) . Like viral proteins, mdm2 protein is also capable of binding to p53 (2) (3) (4) . The complex that develops in this process inactivates the tumor suppressive function of p53 and prevents p53 from intervening into the cell cycle. The functional effect of inactivation through the formation of a p53-mdm2-complex thus corresponds to a complex formation between wild-type p53 and mutated p53 (5) . Moreover, mdm2 is capable of forming complexes with both wild-type p53 and mutated p53. The interaction and relative ratios of p53 and mdm2 protein seem to play an important role in regulating cell division (3) . Simultaneously, mdm2 inhibits the p53 function by binding to its transcriptional activation domain (6) .
Furthermore, it was shown that p53 activates the expression of the mdm2 gene in an autoregulatory feedback loop (7, 8) . Otherwise, the overexpression of mdm2 can reduce the amount of endogenous p53 through enhanced proteasome-dependent degradation (9) . Recent research has suggested that mdm2 also promotes the rapid degradation of p53 under conditions in which p53 is otherwise stabilized (10) .
At the level of amplification or protein overexpression, mdm2 plays a role in a variety of tumors such as sarcomas (11, 12) and epithelial neoplasms, such as breast and lung tumors (13) (14) (15) . In the early gastric carcinogenesis, however, mdm2 protein overexpression seems to play no role (16) . To the best of our knowledge, this study is the first to investigate mdm2 expression and amplification in advanced-stage gastric cancer.
MATERIALS AND METHODS

Tissue
We investigated a series of 43 gastric carcinomas received in the Department of General Surgery, Magdeburg University, between 1995 and 1996. The resected stomachs were sent to the Department of Pathology for rapid section.
In addition to routine preparation, further representative tumor material was prepared, snapfrozen in liquid nitrogen, and stored at Ϫ70°C. All tumors showed a deep invasion of the gastric wall and were classified as advanced-stage cancers according to the pTNM system (pT 2-4). The number, origin, and involvement of the regional lymph nodes excised were also determined according to the International Union Against Cancer TNM system (17) . Clinical data on the presence of metastases were included in this classification. For the histologic tumor typing, Lauren's classification system was used (18) . There were 18 carcinomas of the diffuse type (mean age of patients, 60.9; range, 33 to 76; sex: f/m, 9/9), 20 intestinal cases (mean age of patients, 66.2; range, 34 to 83; sex: f/m, 5/16), and four mixed-type tumors (mean age of patients, 67.5; range, 64 to 71; sex: f/m, 2/2). One tumor was classified as a primary small cell carcinoma of the stomach.
Immunohistology
Mdm2 and p53 protein
Immunohistochemical analyses of p53 and mdm2 protein were performed on formalin-fixed, paraffin-embedded material. For the reactions, standardized and automated immunohistochemistry were applied (Nexes; Ventana Medical Systems, Tucson, AZ). Sections (4 m thick) were deparaffinized in a series of graded alcohols and microwaved in EDTA buffer for 2 ϫ 10 min at 450 W.
After the sections were cooled to room temperature and rinsed with Tris buffer, incubation was performed with anti-p53 (Do-1; Calbiochem, Cambridge, MA) or anti-mdm2 (SMP-14; DAKO, Hamburg, Germany) in an immunostainer. Before incubation of the primary antibodies, endogenous peroxidase was blocked by preincubation of the slides with 0.3% H 2 O 2 . The p53 antibody reacted specifically with both the wild type of protein p53 and its mutant form, recognizing an epitope between the amino acids 37 and 45 (19) . Anti-p53 was diluted 1:30 and incubated at 37°C for 26 min;
anti-mdm2 was diluted 1:50 and incubated at 37°C for 30 min. Bound primary antibodies were detected by the avidin-biotin-complex method (Ventana Medical Systems) labeled with horseradish peroxidase and diaminobenzidine as substrates. All detection steps were performed at 37°C in the immunostainer.
Assessment of both antigens was made by counting 1,000 cells per section at high magnification (high-power field, 40ϫ), and the percentage of positive tumor cells was determined. According to Kawai et al. (20) , a tumor was considered positive for p53 when more than 10% of the tumor cells were immunopositive. With regard to positive mdm2 antibody reaction, the cutoff point was defined as 10%. For both antibodies p53 and mdm2, only the positive nuclear staining was evaluated. Sections from a breast carcinoma were used as a positive control for mdm2 and p53, respectively. The immunohistochemistry slides were evaluated independently by two pathologists (TG and CH).
Molecular Genetic Methods
DNA preparation
DNA was prepared from 2-to 10-mg fresh tissue through a phenol-chloroform extraction (21) .
To estimate the percentage of tumor cells in hematoxylin and eosin slides, tumor tissue corresponding to all snap-frozen tumor samples was obtained. We used only those cases in which at least 70% tumor cells were seen. A dilutional effect caused by nontumor cells on the DNA analysis should thus be excluded.
Mdm2 amplification
Southern blot analysis was performed by 10 g of DNA with EcoRI (AGS, Heidelberg, Germany), separating the fragments by electrophoresis on 0.8% agarose gels, and by transferring them to nylon filters (Amersham Pharmacia Biotech Europe GmbH, Freiburg, Germany). The DNA on the filters was then sequentially hybridized with probes for mdm2 (a cDNA fragment containing Ϫ300 to 1600 nt of the mdm2 gene [i.e., almost the entire coding region, provided by Dr. B. Vogelstein]) and for ␤-actin used as a control (1) for unequal amounts of DNA loaded. Probe labeling was done with the use of random oligonucleotide primers (Gene Images; CDP Star; Amersham Pharmacia Biotech Europe).
Hybridization signals were quantified by densitometry (VDS Amersham Pharmacia Biotech Europe; Dorval, Quebec, Canada; Biotech, Bethesda, MD). Signals that had an intensity at least three times higher than those from samples with a normal copy number of the gene (placenta) were scored as amplification. The osteosarcoma cell line OsA-CL (ATCC, Rockville, MD), in which mdm2 is amplified, was used as a positive control (1).
Polymerase chain reaction-single-strand conformation polymorphism technique
The conserved regions of the p53 gene (exons 4 to 8) were amplified and sequenced. Primers have recently been described by Gü nther et al. (13) .
A total volume of 50 l polymerase chain reaction (PCR) mixture contained 100 ng DNA, 250 M dNTPs, 25 pmol primer each, 1.5 mM MgCl 2 , 1 ϫ PCR buffer: 20 mM Tris-HCl (pH 8.4), 50 mM KCl, and 2.5 u Taq-DNA-polymerase (Life Technologies, Karlsruhe, Germany). PCR consisted of 35 cycles (92°C for 1 min, 52 to 62°C for 5 min, 72°C for 1 min) and was performed in an automated thermocycler (PTC, Watertown, MA).
Routine evidence of the PCR products was given on ultrathin polyacrylamide gels (PAA, 0.3-to 0.45-mm thick, 8 to 15%, depending on the fragment length) at 15°C for approximately 2.5 h in a horizontal electrophoresis system (Multiphor, Pharmacia/Biotech). DNA fragments were demonstrated using a modified silver staining protocol according to Budowle et al. (22) . The single-strand conformation polymorphism (SSCP) technique (23) served as a prescreening method for the detection of mutations. Each PCR product that showed aberrantly migrating single strands was always amplified twice to exclude amplification artifacts. In brief, 4.5 l of the PCR product and 4.5 l of 100% formamide buffer (0.05% bromphenol, 0.05% xylencyanol) were denatured at 98°C for 5 min, subsequently chilled on ice, and applied to a 0.5 ϫ mutation-detection-enhancement gel (AT Biochem). Gels were stained according to a protocol described by Goldman and Merril (24) .
PCR products that showed mobility shifts of their single strands were directly sequenced on an automated fluorescence sequencer (ALF-Express, Pharmacia, Biotech).
Statistical Evaluation
The significance of associations between genetic and immunohistologic findings and clinicopathologic factors was evaluated statistically by Fisher's exact test (two tail) using SAS statistical software system (SAS Institute, Inc., Cary, NC). A probability of P Ͻ .05 was considered significant.
RESULTS
Mdm2
Of 43 gastric carcinomas investigated, 18 (41.8%) showed an amplification of the mdm2 oncogene (Fig. 1) . The gene was upregulated in 9 of 18 (50%) diffuse-type carcinomas, in the small cell carcinoma, and in 3 of the 4 mixed-type tumors. Only 5 of the 20 (25%) intestinal-type carcinomas were found to show mdm2 gene amplification.
The expression of the mdm2 protein could also be demonstrated in 18 tumors. In 9 of 23 (39.1%) carcinomas with a diffuse growth pattern (Fig. 2) , including 2 of the mixed type, the reaction was positive in more than 10% of the tumor cells. Nine of 20 carcinomas of the intestinal type (45%) were mdm2 positive.
Nontumor cells, such as connective tissue cells and smooth muscle cells of the stomach wall or epithelial cells of the mucosa, reacted only occasionally to the mdm2 antibody. Only the parietal cells of the corpus mucosa showed a nonspecific positive immunoreaction. The screening of carcinomas for genetic p53 alterations by SSCP analysis and direct sequencing revealed mutations in 9 of 43 (20.9%) tumors (Figs.  3 and 4) . Only one carcinoma of the diffuse type showed a p53 mutation (5.5%); a second mutation was verified in the small cell carcinoma. Mutations were also seen in 7 of 20 intestinal-type tumors (35%). The four carcinomas with mixed differentiation showed no p53 mutations. The mutation spectrum is presented in Table 1 .
p53 overexpression was demonstrated in 14 of 20 (70%) tumors with a glandular growth pattern (Fig.  5) . Twelve of them were of the intestinal type, and 2 were carcinomas of the mixed type, which expressed p53 in their glandular component. In contrast, the p53 protein was found by immunohistology in only four carcinomas with a diffuse growth pattern. No p53 overexpression was seen in the small cell tumor.
As summarized in Table 2 , tumors with a diffuse growth pattern, including those classified as mixed type and the small cell carcinoma, tended to show a higher frequency of mdm2 amplification than carcinomas of the intestinal type (P ϭ .062). There was also a tendency for p53 gene mutations to occur more frequently in the intestinal type (P ϭ .059).
The mdm2 protein expression showed no differences concerning the tumor type (P ϭ .763), whereas a significantly higher frequency of the p53 protein overexpression could be found in carcinomas of the intestinal type (P ϭ .001).
Altogether, approximately 80% of the gastric carcinomas investigated showed mdm2 and/or p53 alterations (Table 3) , either at the level of genetic changes or at the protein level.
DISCUSSION
Numerous investigations have addressed alterations of the p53 tumor suppressor gene as well as the accumulation of the p53-coded protein in the genesis of different tumors (25) . Several studies have demonstrated that p53 alterations, including protein overexpression, also play a role in the pathogenesis of gastric carcinoma (25, 26) . On the one hand, the functions of the p53 gene, regulating the cell cycle (27) and apoptosis, are disturbed by gene mutations and deletions. On the other hand, both viral proteins and oncoproteins, such as mdm2, may manipulate the p53 function and thus, alternatively, exert an influence on the cell cycle via this pathway (2) (3) (4) . The frequency of the mdm2 amplification in gastric carcinoma has not yet been investigated. Although in our study the mdm2 gene Table 1 ), a heteroduplex formation (arrows) can be seen, reflecting the heterozygous TA insertion confirmed by sequence analysis. (12) . In osteosarcomas, mdm2 upregulation was found in 14% (28) . In contrast, as in Ewing's sarcoma (29) , mdm2 seems to play no role in the pathogenesis of carcinomas of the cervix uteri (30 (26) .
Because only approximately 20% of the gastric carcinomas show mdm2/p53 alterations neither at the genetic nor at the posttranslational level, we can draw the following conclusions: (1) Alterations in the mdm2/p53 pathway are a part of the pathogenesis of gastric carcinoma. (2) Tumors with a diffuse growth pattern in particular are frequently accompanied by an amplification of the mdm2 oncogene during genesis, whereas p53 alterations are expected to occur in intestinal-type carcinomas. The question as to which stage of tumorigenesis allows mdm2 alterations to gain importance remains to be answered in further investigations. ϩ, observed alterations; Ϫ, no gene alterations.
